{"ticker": {"uuid": "4fe8f96d-b502-4ad0-8d9c-cf78282415b7", "symbol": "JUNS", "name": "Jupiter Neurosciences, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Ros\u00e9n & President Alison Silva", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/psychedelic-therapy-meets-m-fireside-172512331.html", "source_name": "IPO-Edge.com", "published_at": "2026-07-22T17:25:12+00:00", "published_display": "22 Jul 2026 17:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CNS drug specialist Jupiter Neuro signs MDMA deal with PharmAla Biotech", "summary": "Jupiter Neurosciences Inc. has secured exclusive U.S. rights to Pharmala Biotech's ALA-002, an MDMA formulation for neuropsychiatric conditions, in a deal valued up to US$100 million. This agreement expands Jupiter's focus from neurodegeneration to also include neuropsychiatric d", "url": "https://mugglehead.com/cns-drug-specialist-jupiter-neuro-signs-mdma-deal-with-pharmala-biotech/", "source_name": "Mugglehead Investment Magazine", "published_at": "2026-07-22T17:40:49", "published_display": "22 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002", "summary": "Jupiter Neurosciences (NASDAQ: JUNS) has signed a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002, a patented, non-racemic MDMA formulation valued at up to $100 million. This acquisition expands Jupiter into a dual c", "url": "https://www.einnews.com/pr_news/928574819/jupiter-neurosciences-nasdaq-juns-signs-definitive-agreement-for-exclusive-u-s-rights-to-ala-002", "source_name": "EIN News", "published_at": "2026-07-22T15:40:49", "published_display": "22 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences acquires US rights to ALA-002 in deal worth up to $100M", "summary": "Jupiter Neurosciences has acquired the U.S. rights to ALA-002, a drug developed by Saneron CCEL Therapeutics for neurological and neuro-ophthalmic disorders, in a deal potentially worth up to $100 million. The agreement includes an upfront payment, milestone payments, and royalti", "url": "https://www.msn.com/en-us/money/general/jupiter-neurosciences-acquires-us-rights-to-ala-002-in-deal-worth-up-to-100m/ar-AA28nBfw", "source_name": "MSN", "published_at": "2026-07-22T15:40:49", "published_display": "22 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences licenses MDMA drug ALA-002", "summary": "Jupiter Neurosciences has licensed exclusive US rights to PharmAla Biotech Holdings' MDMA drug ALA-002, intended for neuropsychiatric disorders like PTSD and anxiety. The deal includes an upfront payment of $3.3 million and potential milestones up to $20 million upon FDA approval", "url": "https://www.bioxconomy.com/partnering/psychedelic-renaissance-continues-as-jupiter-neurosciences-licenses-mdma-asset", "source_name": "BioXconomy", "published_at": "2026-07-22T15:40:49", "published_display": "22 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002", "summary": "PharmAla Biotech Holdings Inc. has announced a definitive license agreement with Jupiter Neurosciences, granting Jupiter exclusive, perpetual U.S. rights to develop, manufacture, and commercialize ALA-002, PharmAla's lead drug candidate. The deal is valued at up to approximately ", "url": "https://investingnews.com/pharmala-biotech-executes-definitive-license-agreement-granting-jupiter-neurosciences-exclusive-u-s-rights-to-ala-002/", "source_name": "Investing News Network", "published_at": "2026-07-21T21:40:23", "published_display": "21 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences (Nasdaq: JUNS) to license ALA-002 in US", "summary": "Jupiter Neurosciences (Nasdaq: JUNS) has entered into a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc., securing exclusive U.S. rights to develop, manufacture, and commercialize ALA-002 for human therapeutic uses. The agreement includes an upfron", "url": "https://www.stocktitan.net/sec-filings/JUNS/8-k-jupiter-neurosciences-inc-reports-material-event-58e2c609aa78.html", "source_name": "Stock Titan", "published_at": "2026-07-21T20:10:59", "published_display": "21 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oracle stock has crashed 50% since June", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPT0lqSEN1YW1rMElHcmFxbjluU2xiYmgtTlBMbVQ3YnYyTkZsNmx2M09BWExwSG9YQndSdHZqblY4WGhJYXNFS2k5dEtielgwMHlGT0c0TUJSY0lDZGlGN0lMRzBPcktBNzhxS2ZqWUp1T2s0a2pmY0J2YklEbTVvSWtjNGtxMk9fWVhOaDJkc2hFczNyWUo1R1V0d1k0aGFuM3JGOA?oc=5", "source_name": "Market source", "published_at": "2026-07-21T13:56:47+00:00", "published_display": "21 Jul 2026 13:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Obtains Exclusive US Rights to Potential Psychedelic Therapy for Up to $100 Million", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/jupiter-neurosciences-obtains-exclusive-us-120023701.html", "source_name": "MT Newswires", "published_at": "2026-07-21T12:00:23+00:00", "published_display": "21 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Tuesday's Pre-Market Session", "summary": "This article identifies 12 healthcare stocks that are experiencing significant movement in pre-market trading on Tuesday. It lists both gainers, such as Jupiter Neurosciences and Imunon, and losers, including Zhengye Biotechnology and Lisata Therapeutics, along with their respect", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60573672/12-health-care-stocks-moving-tuesday-s-pre-market-session", "source_name": "Benzinga", "published_at": "2026-07-21T12:10:59", "published_display": "21 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAla Biotech Executes Definitive License Agreement", "summary": "PharmAla Biotech has entered into a definitive license agreement with Jupiter Neurosciences, granting Jupiter exclusive U.S. rights to develop, manufacture, and commercialize ALA-002, PharmAla\u2019s lead drug candidate. The deal is valued at up to approximately US$100 million, includ", "url": "https://www.globenewswire.com/news-release/2026/07/21/3330301/0/en/pharmala-biotech-executes-definitive-license-agreement-granting-jupiter-neurosciences-exclusive-u-s-rights-to-ala-002.html", "source_name": "GlobeNewswire", "published_at": "2026-07-21T11:10:59", "published_display": "21 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million", "summary": "Jupiter Neurosciences, Inc. (NASDAQ: JUNS) has signed a definitive license agreement with PharmAla Biotech Holdings Inc. for exclusive U.S. rights to ALA-002, a patented, non-racemic MDMA formulation. The transaction is valued at up to $100 million, including milestone payments, ", "url": "https://uk.finance.yahoo.com/news/jupiter-neurosciences-nasdaq-juns-signs-111300530.html", "source_name": "Market source", "published_at": "2026-07-21T11:10:59", "published_display": "21 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAla Retains ALA-002 Rights Outside U.S. in Jupiter License", "summary": "PharmAla Biotech has granted Jupiter Neurosciences exclusive U.S. rights to its lead drug candidate, ALA-002, in a deal worth up to $100 million. PharmAla retains all international rights to ALA-002 and will receive an upfront payment, milestone payments, and royalties on U.S. ne", "url": "https://www.stocktitan.net/news/MDXXF/pharm-ala-biotech-executes-definitive-license-agreement-granting-ealkmh6x2pl3.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:10:59", "published_display": "21 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)", "summary": "Jupiter Neurosciences (NASDAQ:JUNS) has signed an exclusive U.S. licensing agreement with PharmAla Biotech Holdings for ALA-002, a clinical-stage psychedelic therapeutic candidate, valued at up to $100 million. This deal transforms Jupiter into a dual clinical-stage CNS company, ", "url": "https://finance.yahoo.com/healthcare/articles/jupiter-neurosciences-signs-ala-002-142702265.html", "source_name": "Market source", "published_at": "2026-07-21T10:27:00", "published_display": "21 Jul 2026 10:27", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NJ Rep. Tom Kean reaped as much $340K in June stock trades while missing from Congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQZFNwN3psdGJ0ZDB3MWFod1NwRklub1B2ekxIVWo3aklBYlFUeXFYLWk5RDdRdlpzNktocm9WTkxkdk1GTFE0NmFrQXBBYzlGaUFyTzV2TlQ3NHEwcXdnYnJxMkpac3FsTDNfVU1JX1ZKTEt4TEJVaWQ4am40bDBIQncwd1laWDFqOHo0RTVlQmlxNHRFcWE5SDJPVDh0Zjg?oc=5", "source_name": "Gothamist", "published_at": "2026-07-16T16:40:28+00:00", "published_display": "16 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider at Jupiter Neurosciences (JUNS) unlocks 1.01M shares", "summary": "Jupiter Neurosciences' Chief Scientific Officer and director, Marshall A. Hayward, exercised derivative awards, converting 1,014,195 shares into common stock. These transactions included restricted stock awards and stock options, increasing his direct common stock holdings to 2,9", "url": "https://www.stocktitan.net/sec-filings/JUNS/form-4-jupiter-neurosciences-inc-insider-trading-activity-d16132fafa7b.html", "source_name": "Stock Titan", "published_at": "2026-07-15T09:40:23", "published_display": "15 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jupiter Neurosciences Inc (JUNS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Jupiter Neurosciences Inc (JUNS), highlighting its current price momentum, support and resistance levels, and indicator and moving average signals. The stock currently has a price momentum score of 5.55, trading between resistance at ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-juns/technical", "source_name": "TradingKey", "published_at": "2026-07-11T06:10:21", "published_display": "11 Jul 2026 06:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson", "summary": "Jupiter Neurosciences, Inc. (Nasdaq: JUNS) has appointed Dr. Tomas J. Philipson, a distinguished health care economist and former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson will serve on both ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/JUNS-Q/pressreleases/3162442/jupiter-neurosciences-strengthens-board-with-appointment-of-dr-tomas-j-philipson/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T07:09:58", "published_display": "09 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Strengthens Bd With Appointment of Dr. Tomas J. Philipson", "summary": "Jupiter Neurosciences has announced the appointment of Dr. Tomas J. Philipson to its Board of Directors. Dr. Philipson brings extensive experience in economics, healthcare, and public policy, having served in significant roles including former Acting Chairman of the Council of Ec", "url": "https://www.moomoo.com/news/post/72588443/jupiter-neurosciences-strengthens-bd-with-appointment-of-dr-tomas-j", "source_name": "Moomoo", "published_at": "2026-07-08T06:10:21", "published_display": "08 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences appoints Tomas Philipson to board", "summary": "Jupiter Neurosciences, Inc. (NASDAQ:JUNS) has appointed Dr. Tomas J. Philipson, a former acting chairman of the White House Council of Economic Advisers, to its Board of Directors, where he will serve on the Audit and Compensation Committees. Dr. Philipson, a health care economis", "url": "https://www.investing.com/news/company-news/jupiter-neurosciences-appoints-tomas-philipson-to-board-93CH-4779465", "source_name": "Investing.com", "published_at": "2026-07-07T13:41:31", "published_display": "07 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Appoints Former White House CEA Acting Chairman Tomas J. Philipson to Board of Directors", "summary": "Jupiter Neurosciences, Inc. has appointed Tomas J. Philipson, Ph.D., former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson, a distinguished health care economist, will bring extensive experience i", "url": "https://www.quiverquant.com/news/Jupiter+Neurosciences+Appoints+Former+White+House+CEA+Acting+Chairman+Tomas+J.+Philipson+to+Board+of+Directors", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T13:01:00", "published_display": "07 Jul 2026 13:01", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences (JUNS) director Tomas Jan Philipson files Form 3", "summary": "Jupiter Neurosciences (JUNS) director Tomas Jan Philipson has filed an initial Form 3, indicating his status as a director but not a ten percent owner of the company. The filing reports no insider transactions, exercises, gifts, or derivative holdings at this time. This Form 3 is", "url": "https://www.stocktitan.net/sec-filings/JUNS/form-3-jupiter-neurosciences-inc-initial-statement-of-beneficial-owne-0c2ac6523cae.html", "source_name": "Stock Titan", "published_at": "2026-07-05T08:11:10", "published_display": "05 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Jupiter Neurosciences, Inc. \u2013 NASDAQ:JUNS", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOY0ZyWFJFWmczc25HbXhQZmR4QW10blFKeTR1VzdWXzJWN2JSSkdEamVvYWptUFZNSjFRb1VYbzF5LWt4djlhbjhXV190YmM0aDYyb0JBNkxxSnpqOExfRWxkWTZmWjZIX2o1T1VUbGtRTlpPMzBnNHdOM2FaLVoxaWhpbEptMUYzeENPYUdnVGhlZGZIdERiM09HTVd4TFdXenB0M1FkcDNaN2RNcnc?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T02:13:27+00:00", "published_display": "05 Jul 2026 02:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Jupiter Neurosciences, Inc. \u2013 NASDAQ:JUNS", "summary": "The article provides a single financial metric, the \"Price to book forward,\" for Jupiter Neurosciences, Inc. (NASDAQ: JUNS). It notes that the market for this stock is currently closed with no trades. The information is presented within the context of a TradingView financial data", "url": "https://www.tradingview.com/symbols/NASDAQ-JUNS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:39:17", "published_display": "05 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Jupiter Neurosciences, Inc. \u2013 NASDAQ:JUNS", "summary": "This article provides a financial metric, the enterprise value to revenue forward, for Jupiter Neurosciences, Inc. (NASDAQ: JUNS). The content is primarily a placeholder or incomplete financial data summary from TradingView, focusing on the company's stock information and general", "url": "https://www.tradingview.com/symbols/NASDAQ-JUNS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T16:10:14", "published_display": "03 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences | 424B3: Prospectus", "summary": "This entry is a 424B3 prospectus filing for Jupiter Neurosciences, a standard regulatory document submitted to the SEC. It provides detailed information about a registered securities offering.", "url": "https://www.moomoo.com/news/notice/307638635/jupiter-neurosciences-424b3-prospectus", "source_name": "Moomoo", "published_at": "2026-07-01T04:11:26", "published_display": "01 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-1 Jupiter Neurosciences Inc For: 26 June By Investing.com", "summary": "This article announces that Jupiter Neurosciences Inc. filed a Form S-1 on June 26th. The filing is a public record indicating Jupiter Neurosciences' intent to go public or issue new shares. The main content of the article is a short statement about the S-1 filing, accompanied by", "url": "https://ng.investing.com/news/stock-market-news/form-s1-jupiter-neurosciences-inc-for-26-june-93CH-2576671", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T14:13:51", "published_display": "27 Jun 2026 14:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences files for resale of up to 16M shares by Yorkville", "summary": "Jupiter Neurosciences, Inc. has filed a prospectus for the resale of up to 16 million shares by YA II PN, LTD (Yorkville) under a standby equity purchase agreement. While the company will not receive proceeds from this specific resale, it has the potential to receive up to $17.2 ", "url": "https://scanx.trade/stock-market-news/ipo/jupiter-neurosciences-files-for-resale-of-up-to-16m-shares-by-yorkville/44052133", "source_name": "scanx.trade", "published_at": "2026-06-26T21:40:13", "published_display": "26 Jun 2026 21:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Yorkville to resell 16M Jupiter Neurosciences (NASDAQ: JUNS) shares under SEPA", "summary": "Jupiter Neurosciences has registered 16 million shares of common stock for resale by Yorkville under a Standby Equity Purchase Agreement (SEPA), which could provide up to $20 million in equity financing. This move could lead to significant dilution for existing shareholders, as t", "url": "https://www.stocktitan.net/sec-filings/JUNS/s-1-jupiter-neurosciences-inc-files-ipo-registration-statement-eec93ee65bee.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:40:13", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences - Files For Resale Of Up To 16 Million Shares By Selling Stockholder - SEC Filing", "summary": "Jupiter Neurosciences has filed with the SEC for the resale of up to 16 million shares by a selling stockholder. This information was reported via Refinitiv and is an SEC filing.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42Y0I8:0-jupiter-neurosciences-files-for-resale-of-up-to-16-million-shares-by-selling-stockholder-sec-filing/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:13", "published_display": "26 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 26, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNUlBOOEFNQUlRQVltVDlPY05PUGt5Zm5rTnFuOUFRZGlnbi1OR2Q2bjVlTGxwdXBubFpOT1gyOERQWm1yV1ZMQmUyUDlYdnUzWjhlTlRkZm9wZUVuWmYySk5qRkpQckdxN0V6OFlubXFiZEp1VmFzMEdwcTZ3Y0dQc2g0QjRvR2NQUFkwNUE5WkM2QW8?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences, Inc. Actuals & Estimates (NASDAQ:JUNS)", "summary": "This article provides a detailed overview of Jupiter Neurosciences, Inc. (JUNS) stock, including its current price, market capitalization, volatility, and historical performance. It also covers financial actuals and estimates, confirming that the company does not pay dividends an", "url": "https://www.tradingview.com/symbols/NASDAQ-JUNS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:39:40", "published_display": "25 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 25, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQUlpkVDNRakthVW9La1BTdjV2Qll5M09ib2hRR05MakE0cUkzQjBPLW1jUDdxejdNRjhTdWxuZGxaWVFnRklEUFRKT0hYQ0FlQXdHdEpiVzRmMW5VLURTVkJnaVFQMjRwQ3VKWkVwMnhDRTdlWEM2NDhIbVdqYlkxUVhmTDNKNFprdnpUQTZYTlJRUDg?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JUNS - Jupiter Neurosciences Inc Earnings", "summary": "This article provides a detailed financial overview and key performance indicators for Jupiter Neurosciences Inc. (JUNS). It includes data on market capitalization, enterprise value, income, sales, various P/E and P/S ratios, debt metrics, insider ownership, profitability margins", "url": "https://finviz.com/stock?t=JUNS&p=w&ty=ea", "source_name": "Finviz", "published_at": "2026-06-25T02:10:49", "published_display": "25 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 24, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOM0hBWDJPejZUa1FMTUNtRTdoaGxiYk9ub3dmOU1WUmpsOGszQlZsQkFCcHlCbVV5b3NVNU1Ldm05UlZvbEZRc3pNazU5RmR3VnhQOXctankybkhUX0FTbEFCNEg4bUpVUDZQQmZNXzFTOThUUjRDeHN0WW5DTTliSWkwazBHaGN2YlpzVVh1SWZPa1k?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 23, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPQklIVmFCVFNyZndDX3VleC13Vy1MdzRUMVRoRHR3cFN6cFpmRVJVdjhrMTVTVG12VFZTMDFvckk0c0ViT1dTWEJHNURHMkd4aHJpSGtuVFBzbnpTdTZoZ1FhbnVXczI3X1FZUlNWMlVUcHlMU3NuUC1NMDFEbGJpeFVhSFpQQkJYV3lfeWVhM2w4M3M?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 22, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNZ3lDOUV5TzhaaERxdEJmTmlrUEJMb1RGU1hZUmV3aDV4R0JNWm93RDRyNjcyM1Q4amZIeV9qRHVsckhwRzRsTDNibU1fNWJybnVxODFlLTQxUkJrYmZUcGd0ZmVieS1pUF9rbC1YS2VsdU12SmlYRVN5TDlld0xIV0JMTnVlRlNZOFBzT2JzVUotWmc?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 16, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNMXNJT2gxRlVvbHprU0o1MjFONXFkTEhjejZ6SThOdUZoS3hEcU82aklFWi1LYzdkOUZjWU5IMlVORHJELXRheEd2ZVR1cWtpbEF6SXRONGtLdlpzSTZDcEotaFJvcmozdlVWT1dob1ZOQmFKaFh2LTF4MkhNUFl5YWtxZzhMaWE5SWx1MWlzd0IwZGM?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Stock Picks for Week of June 8, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQSVZzTWp4RnQ4dHhiZk1oOW9BSUVvMTI5S1I5WC1hZ1hGOUpnSzlPUm9JZlZMdFVSYlFVN0Z4RVlRckV5ZDFvM0JObkJUOWdmVTc0Q3pFSlljVVdUMzAtRG9RMWdveGF5UDlJNmQ2Z013dG1sS1BuNTV3RkVTS0Z3SFFkSUtVM3dwdVBwRjBPRWJHekFz?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/d-boral-capital-acted-exclusive-160000495.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-26T16:00:00+00:00", "published_display": "26 May 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPRXlUWm8tQ09OUURiUmxEVmxoNnkzdXVNZ0oxTXpxZ3pOVUZQdzZpVU4tcklRbXZPX1pJdmo1QjhQRkxKM1dyVmtIdXR5YUpqU3ZPNElmWFRzT3llcGZPUlFVZFNiT2tndTg5bHNMNjR0UzlqQWZzd014UG81dE5scVQzZTBMSUtxSERtbWdGb3RNTVRtZ09SenM2dFBFWERaMjdUMGI5WGc2SnM3?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. in a Transaction Valued at Over $100 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAJBVV95cUxPTEFyN1NxWlBhbG1aY0NCWEQ1bXBHNjRqNUpDZnlpaG9PMnJuZlJObUFUQXdzV3FLY1lUUy1lTFRkWWNGMnhLTVh4REdUQjFoM0VoendwZExSZlJXRmVMVi13bnJTMC13R0JqQ21lSElLejZiNzU5cXl3dElFMFRzem5OYXgwekthZGM2YUZGUVJZR0M0UXoweU9UemJ4Q0hPdndObm9BcllvWExwVjV6NGIzTVRqdGpaV1ZqbFJ6bzEteTVkWjQxenZNXzh6WkhOLXN5UWV3WkhoblpkWlppbGstZlRsNk9EaDdYUkl4ajlGTVNfTjZkTlQ2Wm4zaTVxbzA3QnpLNEVwLWp5MnB1TGN6Vk1XRTVPTkhXS2stRWZHaDlXLTk1RVpGSGlsSS0zQ1lURHYyZTA?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Trump psychedelics order, Jupiter signs $100M MDMA term sheet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNVElRMFV2QTh1ZzltMTBIZzhXbFo0dUJnbG9DSU5MSHJtQ1hKZWxmM0J1cTV1ZUxHckt4UGVHRklSdktYMlh3eFZNSkFidm5IV3dLdnRCWFlGU25IWExXakxwT1pBYl9GdHh1LW54TjRJSlNvS3l6RnV4ckVMd25aVXRPbHg5bXo3ektzMjBGTk9VSmszSFpOR3dfNU5zTjlIVTJKVHZrd1hwdy00WDZLR3BuQlVmdlVQS1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Ros\u00e9n & President Alison Silva", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/psychedelic-therapy-meets-m-fireside-172512331.html", "source_name": "IPO-Edge.com", "published_at": "2026-07-22T17:25:12+00:00", "published_display": "22 Jul 2026 17:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CNS drug specialist Jupiter Neuro signs MDMA deal with PharmAla Biotech", "summary": "Jupiter Neurosciences Inc. has secured exclusive U.S. rights to Pharmala Biotech's ALA-002, an MDMA formulation for neuropsychiatric conditions, in a deal valued up to US$100 million. This agreement expands Jupiter's focus from neurodegeneration to also include neuropsychiatric d", "url": "https://mugglehead.com/cns-drug-specialist-jupiter-neuro-signs-mdma-deal-with-pharmala-biotech/", "source_name": "Mugglehead Investment Magazine", "published_at": "2026-07-22T17:40:49", "published_display": "22 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002", "summary": "Jupiter Neurosciences (NASDAQ: JUNS) has signed a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002, a patented, non-racemic MDMA formulation valued at up to $100 million. This acquisition expands Jupiter into a dual c", "url": "https://www.einnews.com/pr_news/928574819/jupiter-neurosciences-nasdaq-juns-signs-definitive-agreement-for-exclusive-u-s-rights-to-ala-002", "source_name": "EIN News", "published_at": "2026-07-22T15:40:49", "published_display": "22 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences acquires US rights to ALA-002 in deal worth up to $100M", "summary": "Jupiter Neurosciences has acquired the U.S. rights to ALA-002, a drug developed by Saneron CCEL Therapeutics for neurological and neuro-ophthalmic disorders, in a deal potentially worth up to $100 million. The agreement includes an upfront payment, milestone payments, and royalti", "url": "https://www.msn.com/en-us/money/general/jupiter-neurosciences-acquires-us-rights-to-ala-002-in-deal-worth-up-to-100m/ar-AA28nBfw", "source_name": "MSN", "published_at": "2026-07-22T15:40:49", "published_display": "22 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences licenses MDMA drug ALA-002", "summary": "Jupiter Neurosciences has licensed exclusive US rights to PharmAla Biotech Holdings' MDMA drug ALA-002, intended for neuropsychiatric disorders like PTSD and anxiety. The deal includes an upfront payment of $3.3 million and potential milestones up to $20 million upon FDA approval", "url": "https://www.bioxconomy.com/partnering/psychedelic-renaissance-continues-as-jupiter-neurosciences-licenses-mdma-asset", "source_name": "BioXconomy", "published_at": "2026-07-22T15:40:49", "published_display": "22 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002", "summary": "PharmAla Biotech Holdings Inc. has announced a definitive license agreement with Jupiter Neurosciences, granting Jupiter exclusive, perpetual U.S. rights to develop, manufacture, and commercialize ALA-002, PharmAla's lead drug candidate. The deal is valued at up to approximately ", "url": "https://investingnews.com/pharmala-biotech-executes-definitive-license-agreement-granting-jupiter-neurosciences-exclusive-u-s-rights-to-ala-002/", "source_name": "Investing News Network", "published_at": "2026-07-21T21:40:23", "published_display": "21 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences (Nasdaq: JUNS) to license ALA-002 in US", "summary": "Jupiter Neurosciences (Nasdaq: JUNS) has entered into a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc., securing exclusive U.S. rights to develop, manufacture, and commercialize ALA-002 for human therapeutic uses. The agreement includes an upfron", "url": "https://www.stocktitan.net/sec-filings/JUNS/8-k-jupiter-neurosciences-inc-reports-material-event-58e2c609aa78.html", "source_name": "Stock Titan", "published_at": "2026-07-21T20:10:59", "published_display": "21 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oracle stock has crashed 50% since June", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPT0lqSEN1YW1rMElHcmFxbjluU2xiYmgtTlBMbVQ3YnYyTkZsNmx2M09BWExwSG9YQndSdHZqblY4WGhJYXNFS2k5dEtielgwMHlGT0c0TUJSY0lDZGlGN0lMRzBPcktBNzhxS2ZqWUp1T2s0a2pmY0J2YklEbTVvSWtjNGtxMk9fWVhOaDJkc2hFczNyWUo1R1V0d1k0aGFuM3JGOA?oc=5", "source_name": "Market source", "published_at": "2026-07-21T13:56:47+00:00", "published_display": "21 Jul 2026 13:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Obtains Exclusive US Rights to Potential Psychedelic Therapy for Up to $100 Million", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/jupiter-neurosciences-obtains-exclusive-us-120023701.html", "source_name": "MT Newswires", "published_at": "2026-07-21T12:00:23+00:00", "published_display": "21 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Tuesday's Pre-Market Session", "summary": "This article identifies 12 healthcare stocks that are experiencing significant movement in pre-market trading on Tuesday. It lists both gainers, such as Jupiter Neurosciences and Imunon, and losers, including Zhengye Biotechnology and Lisata Therapeutics, along with their respect", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60573672/12-health-care-stocks-moving-tuesday-s-pre-market-session", "source_name": "Benzinga", "published_at": "2026-07-21T12:10:59", "published_display": "21 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAla Biotech Executes Definitive License Agreement", "summary": "PharmAla Biotech has entered into a definitive license agreement with Jupiter Neurosciences, granting Jupiter exclusive U.S. rights to develop, manufacture, and commercialize ALA-002, PharmAla\u2019s lead drug candidate. The deal is valued at up to approximately US$100 million, includ", "url": "https://www.globenewswire.com/news-release/2026/07/21/3330301/0/en/pharmala-biotech-executes-definitive-license-agreement-granting-jupiter-neurosciences-exclusive-u-s-rights-to-ala-002.html", "source_name": "GlobeNewswire", "published_at": "2026-07-21T11:10:59", "published_display": "21 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million", "summary": "Jupiter Neurosciences, Inc. (NASDAQ: JUNS) has signed a definitive license agreement with PharmAla Biotech Holdings Inc. for exclusive U.S. rights to ALA-002, a patented, non-racemic MDMA formulation. The transaction is valued at up to $100 million, including milestone payments, ", "url": "https://uk.finance.yahoo.com/news/jupiter-neurosciences-nasdaq-juns-signs-111300530.html", "source_name": "Market source", "published_at": "2026-07-21T11:10:59", "published_display": "21 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAla Retains ALA-002 Rights Outside U.S. in Jupiter License", "summary": "PharmAla Biotech has granted Jupiter Neurosciences exclusive U.S. rights to its lead drug candidate, ALA-002, in a deal worth up to $100 million. PharmAla retains all international rights to ALA-002 and will receive an upfront payment, milestone payments, and royalties on U.S. ne", "url": "https://www.stocktitan.net/news/MDXXF/pharm-ala-biotech-executes-definitive-license-agreement-granting-ealkmh6x2pl3.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:10:59", "published_display": "21 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)", "summary": "Jupiter Neurosciences (NASDAQ:JUNS) has signed an exclusive U.S. licensing agreement with PharmAla Biotech Holdings for ALA-002, a clinical-stage psychedelic therapeutic candidate, valued at up to $100 million. This deal transforms Jupiter into a dual clinical-stage CNS company, ", "url": "https://finance.yahoo.com/healthcare/articles/jupiter-neurosciences-signs-ala-002-142702265.html", "source_name": "Market source", "published_at": "2026-07-21T10:27:00", "published_display": "21 Jul 2026 10:27", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NJ Rep. Tom Kean reaped as much $340K in June stock trades while missing from Congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQZFNwN3psdGJ0ZDB3MWFod1NwRklub1B2ekxIVWo3aklBYlFUeXFYLWk5RDdRdlpzNktocm9WTkxkdk1GTFE0NmFrQXBBYzlGaUFyTzV2TlQ3NHEwcXdnYnJxMkpac3FsTDNfVU1JX1ZKTEt4TEJVaWQ4am40bDBIQncwd1laWDFqOHo0RTVlQmlxNHRFcWE5SDJPVDh0Zjg?oc=5", "source_name": "Gothamist", "published_at": "2026-07-16T16:40:28+00:00", "published_display": "16 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider at Jupiter Neurosciences (JUNS) unlocks 1.01M shares", "summary": "Jupiter Neurosciences' Chief Scientific Officer and director, Marshall A. Hayward, exercised derivative awards, converting 1,014,195 shares into common stock. These transactions included restricted stock awards and stock options, increasing his direct common stock holdings to 2,9", "url": "https://www.stocktitan.net/sec-filings/JUNS/form-4-jupiter-neurosciences-inc-insider-trading-activity-d16132fafa7b.html", "source_name": "Stock Titan", "published_at": "2026-07-15T09:40:23", "published_display": "15 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Inc (JUNS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Jupiter Neurosciences Inc (JUNS), highlighting its current price momentum, support and resistance levels, and indicator and moving average signals. The stock currently has a price momentum score of 5.55, trading between resistance at ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-juns/technical", "source_name": "TradingKey", "published_at": "2026-07-11T06:10:21", "published_display": "11 Jul 2026 06:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson", "summary": "Jupiter Neurosciences, Inc. (Nasdaq: JUNS) has appointed Dr. Tomas J. Philipson, a distinguished health care economist and former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson will serve on both ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/JUNS-Q/pressreleases/3162442/jupiter-neurosciences-strengthens-board-with-appointment-of-dr-tomas-j-philipson/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T07:09:58", "published_display": "09 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Strengthens Bd With Appointment of Dr. Tomas J. Philipson", "summary": "Jupiter Neurosciences has announced the appointment of Dr. Tomas J. Philipson to its Board of Directors. Dr. Philipson brings extensive experience in economics, healthcare, and public policy, having served in significant roles including former Acting Chairman of the Council of Ec", "url": "https://www.moomoo.com/news/post/72588443/jupiter-neurosciences-strengthens-bd-with-appointment-of-dr-tomas-j", "source_name": "Moomoo", "published_at": "2026-07-08T06:10:21", "published_display": "08 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences appoints Tomas Philipson to board", "summary": "Jupiter Neurosciences, Inc. (NASDAQ:JUNS) has appointed Dr. Tomas J. Philipson, a former acting chairman of the White House Council of Economic Advisers, to its Board of Directors, where he will serve on the Audit and Compensation Committees. Dr. Philipson, a health care economis", "url": "https://www.investing.com/news/company-news/jupiter-neurosciences-appoints-tomas-philipson-to-board-93CH-4779465", "source_name": "Investing.com", "published_at": "2026-07-07T13:41:31", "published_display": "07 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Appoints Former White House CEA Acting Chairman Tomas J. Philipson to Board of Directors", "summary": "Jupiter Neurosciences, Inc. has appointed Tomas J. Philipson, Ph.D., former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson, a distinguished health care economist, will bring extensive experience i", "url": "https://www.quiverquant.com/news/Jupiter+Neurosciences+Appoints+Former+White+House+CEA+Acting+Chairman+Tomas+J.+Philipson+to+Board+of+Directors", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T13:01:00", "published_display": "07 Jul 2026 13:01", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences (JUNS) director Tomas Jan Philipson files Form 3", "summary": "Jupiter Neurosciences (JUNS) director Tomas Jan Philipson has filed an initial Form 3, indicating his status as a director but not a ten percent owner of the company. The filing reports no insider transactions, exercises, gifts, or derivative holdings at this time. This Form 3 is", "url": "https://www.stocktitan.net/sec-filings/JUNS/form-3-jupiter-neurosciences-inc-initial-statement-of-beneficial-owne-0c2ac6523cae.html", "source_name": "Stock Titan", "published_at": "2026-07-05T08:11:10", "published_display": "05 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Jupiter Neurosciences, Inc. \u2013 NASDAQ:JUNS", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOY0ZyWFJFWmczc25HbXhQZmR4QW10blFKeTR1VzdWXzJWN2JSSkdEamVvYWptUFZNSjFRb1VYbzF5LWt4djlhbjhXV190YmM0aDYyb0JBNkxxSnpqOExfRWxkWTZmWjZIX2o1T1VUbGtRTlpPMzBnNHdOM2FaLVoxaWhpbEptMUYzeENPYUdnVGhlZGZIdERiM09HTVd4TFdXenB0M1FkcDNaN2RNcnc?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T02:13:27+00:00", "published_display": "05 Jul 2026 02:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Jupiter Neurosciences, Inc. \u2013 NASDAQ:JUNS", "summary": "The article provides a single financial metric, the \"Price to book forward,\" for Jupiter Neurosciences, Inc. (NASDAQ: JUNS). It notes that the market for this stock is currently closed with no trades. The information is presented within the context of a TradingView financial data", "url": "https://www.tradingview.com/symbols/NASDAQ-JUNS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:39:17", "published_display": "05 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Jupiter Neurosciences, Inc. \u2013 NASDAQ:JUNS", "summary": "This article provides a financial metric, the enterprise value to revenue forward, for Jupiter Neurosciences, Inc. (NASDAQ: JUNS). The content is primarily a placeholder or incomplete financial data summary from TradingView, focusing on the company's stock information and general", "url": "https://www.tradingview.com/symbols/NASDAQ-JUNS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T16:10:14", "published_display": "03 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences | 424B3: Prospectus", "summary": "This entry is a 424B3 prospectus filing for Jupiter Neurosciences, a standard regulatory document submitted to the SEC. It provides detailed information about a registered securities offering.", "url": "https://www.moomoo.com/news/notice/307638635/jupiter-neurosciences-424b3-prospectus", "source_name": "Moomoo", "published_at": "2026-07-01T04:11:26", "published_display": "01 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-1 Jupiter Neurosciences Inc For: 26 June By Investing.com", "summary": "This article announces that Jupiter Neurosciences Inc. filed a Form S-1 on June 26th. The filing is a public record indicating Jupiter Neurosciences' intent to go public or issue new shares. The main content of the article is a short statement about the S-1 filing, accompanied by", "url": "https://ng.investing.com/news/stock-market-news/form-s1-jupiter-neurosciences-inc-for-26-june-93CH-2576671", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T14:13:51", "published_display": "27 Jun 2026 14:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences files for resale of up to 16M shares by Yorkville", "summary": "Jupiter Neurosciences, Inc. has filed a prospectus for the resale of up to 16 million shares by YA II PN, LTD (Yorkville) under a standby equity purchase agreement. While the company will not receive proceeds from this specific resale, it has the potential to receive up to $17.2 ", "url": "https://scanx.trade/stock-market-news/ipo/jupiter-neurosciences-files-for-resale-of-up-to-16m-shares-by-yorkville/44052133", "source_name": "scanx.trade", "published_at": "2026-06-26T21:40:13", "published_display": "26 Jun 2026 21:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Yorkville to resell 16M Jupiter Neurosciences (NASDAQ: JUNS) shares under SEPA", "summary": "Jupiter Neurosciences has registered 16 million shares of common stock for resale by Yorkville under a Standby Equity Purchase Agreement (SEPA), which could provide up to $20 million in equity financing. This move could lead to significant dilution for existing shareholders, as t", "url": "https://www.stocktitan.net/sec-filings/JUNS/s-1-jupiter-neurosciences-inc-files-ipo-registration-statement-eec93ee65bee.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:40:13", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences - Files For Resale Of Up To 16 Million Shares By Selling Stockholder - SEC Filing", "summary": "Jupiter Neurosciences has filed with the SEC for the resale of up to 16 million shares by a selling stockholder. This information was reported via Refinitiv and is an SEC filing.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42Y0I8:0-jupiter-neurosciences-files-for-resale-of-up-to-16-million-shares-by-selling-stockholder-sec-filing/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:13", "published_display": "26 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 26, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNUlBOOEFNQUlRQVltVDlPY05PUGt5Zm5rTnFuOUFRZGlnbi1OR2Q2bjVlTGxwdXBubFpOT1gyOERQWm1yV1ZMQmUyUDlYdnUzWjhlTlRkZm9wZUVuWmYySk5qRkpQckdxN0V6OFlubXFiZEp1VmFzMEdwcTZ3Y0dQc2g0QjRvR2NQUFkwNUE5WkM2QW8?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences, Inc. Actuals & Estimates (NASDAQ:JUNS)", "summary": "This article provides a detailed overview of Jupiter Neurosciences, Inc. (JUNS) stock, including its current price, market capitalization, volatility, and historical performance. It also covers financial actuals and estimates, confirming that the company does not pay dividends an", "url": "https://www.tradingview.com/symbols/NASDAQ-JUNS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:39:40", "published_display": "25 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 25, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQUlpkVDNRakthVW9La1BTdjV2Qll5M09ib2hRR05MakE0cUkzQjBPLW1jUDdxejdNRjhTdWxuZGxaWVFnRklEUFRKT0hYQ0FlQXdHdEpiVzRmMW5VLURTVkJnaVFQMjRwQ3VKWkVwMnhDRTdlWEM2NDhIbVdqYlkxUVhmTDNKNFprdnpUQTZYTlJRUDg?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JUNS - Jupiter Neurosciences Inc Earnings", "summary": "This article provides a detailed financial overview and key performance indicators for Jupiter Neurosciences Inc. (JUNS). It includes data on market capitalization, enterprise value, income, sales, various P/E and P/S ratios, debt metrics, insider ownership, profitability margins", "url": "https://finviz.com/stock?t=JUNS&p=w&ty=ea", "source_name": "Finviz", "published_at": "2026-06-25T02:10:49", "published_display": "25 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 24, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOM0hBWDJPejZUa1FMTUNtRTdoaGxiYk9ub3dmOU1WUmpsOGszQlZsQkFCcHlCbVV5b3NVNU1Ldm05UlZvbEZRc3pNazU5RmR3VnhQOXctankybkhUX0FTbEFCNEg4bUpVUDZQQmZNXzFTOThUUjRDeHN0WW5DTTliSWkwazBHaGN2YlpzVVh1SWZPa1k?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 23, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPQklIVmFCVFNyZndDX3VleC13Vy1MdzRUMVRoRHR3cFN6cFpmRVJVdjhrMTVTVG12VFZTMDFvckk0c0ViT1dTWEJHNURHMkd4aHJpSGtuVFBzbnpTdTZoZ1FhbnVXczI3X1FZUlNWMlVUcHlMU3NuUC1NMDFEbGJpeFVhSFpQQkJYV3lfeWVhM2w4M3M?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 22, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNZ3lDOUV5TzhaaERxdEJmTmlrUEJMb1RGU1hZUmV3aDV4R0JNWm93RDRyNjcyM1Q4amZIeV9qRHVsckhwRzRsTDNibU1fNWJybnVxODFlLTQxUkJrYmZUcGd0ZmVieS1pUF9rbC1YS2VsdU12SmlYRVN5TDlld0xIV0JMTnVlRlNZOFBzT2JzVUotWmc?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market News for Jun 16, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNMXNJT2gxRlVvbHprU0o1MjFONXFkTEhjejZ6SThOdUZoS3hEcU82aklFWi1LYzdkOUZjWU5IMlVORHJELXRheEd2ZVR1cWtpbEF6SXRONGtLdlpzSTZDcEotaFJvcmozdlVWT1dob1ZOQmFKaFh2LTF4MkhNUFl5YWtxZzhMaWE5SWx1MWlzd0IwZGM?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Stock Picks for Week of June 8, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQSVZzTWp4RnQ4dHhiZk1oOW9BSUVvMTI5S1I5WC1hZ1hGOUpnSzlPUm9JZlZMdFVSYlFVN0Z4RVlRckV5ZDFvM0JObkJUOWdmVTc0Q3pFSlljVVdUMzAtRG9RMWdveGF5UDlJNmQ2Z013dG1sS1BuNTV3RkVTS0Z3SFFkSUtVM3dwdVBwRjBPRWJHekFz?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/d-boral-capital-acted-exclusive-160000495.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-26T16:00:00+00:00", "published_display": "26 May 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPRXlUWm8tQ09OUURiUmxEVmxoNnkzdXVNZ0oxTXpxZ3pOVUZQdzZpVU4tcklRbXZPX1pJdmo1QjhQRkxKM1dyVmtIdXR5YUpqU3ZPNElmWFRzT3llcGZPUlFVZFNiT2tndTg5bHNMNjR0UzlqQWZzd014UG81dE5scVQzZTBMSUtxSERtbWdGb3RNTVRtZ09SenM2dFBFWERaMjdUMGI5WGc2SnM3?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. in a Transaction Valued at Over $100 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAJBVV95cUxPTEFyN1NxWlBhbG1aY0NCWEQ1bXBHNjRqNUpDZnlpaG9PMnJuZlJObUFUQXdzV3FLY1lUUy1lTFRkWWNGMnhLTVh4REdUQjFoM0VoendwZExSZlJXRmVMVi13bnJTMC13R0JqQ21lSElLejZiNzU5cXl3dElFMFRzem5OYXgwekthZGM2YUZGUVJZR0M0UXoweU9UemJ4Q0hPdndObm9BcllvWExwVjV6NGIzTVRqdGpaV1ZqbFJ6bzEteTVkWjQxenZNXzh6WkhOLXN5UWV3WkhoblpkWlppbGstZlRsNk9EaDdYUkl4ajlGTVNfTjZkTlQ2Wm4zaTVxbzA3QnpLNEVwLWp5MnB1TGN6Vk1XRTVPTkhXS2stRWZHaDlXLTk1RVpGSGlsSS0zQ1lURHYyZTA?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Trump psychedelics order, Jupiter signs $100M MDMA term sheet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNVElRMFV2QTh1ZzltMTBIZzhXbFo0dUJnbG9DSU5MSHJtQ1hKZWxmM0J1cTV1ZUxHckt4UGVHRklSdktYMlh3eFZNSkFidm5IV3dLdnRCWFlGU25IWExXakxwT1pBYl9GdHh1LW54TjRJSlNvS3l6RnV4ckVMd25aVXRPbHg5bXo3ektzMjBGTk9VSmszSFpOR3dfNU5zTjlIVTJKVHZrd1hwdy00WDZLR3BuQlVmdlVQS1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 63, "sentiment_summary": {"positive": 20, "negative": 7, "neutral": 36, "score": 56, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 21.25, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 8.05, "count": 16}, {"event": "deals", "label": "Deals and strategy", "weight": 4.4, "count": 8}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 0.17, "latest_week": "2026-07-17", "one_week_move": -9.2, "four_week_move": -27.5, "twelve_week_move": -55.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.045725, "market_dynamics_buy_signal": false, "relative_strength": -82.44168, "fair_value_gap": -88.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.2205, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.2% over one week, -27.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 19}, {"label": "TradingView", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "Investing News Network", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "IPO-Edge.com", "count": 1}, {"label": "Mugglehead Investment Magazine", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 16}, {"label": "Deals and strategy", "count": 8}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.2% over one week, -27.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Ros\u00e9n & President Alison Silva"}], "updated_at": "2026-07-23T01:59:02.681721+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}